Oxford BioDynamics (LON:OBD) Announces Earnings Results

Oxford BioDynamics (LON:OBD) posted its quarterly earnings data on Wednesday. The biotechnology company reported GBX (0.80) earnings per share for the quarter, Digital Look Earnings reports. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

Oxford BioDynamics Price Performance

Shares of OBD stock opened at GBX 0.23 on Wednesday. The company has a market capitalization of £9.78 million, a P/E ratio of -0.08 and a beta of 0.42. The company’s 50-day simple moving average is GBX 0.30 and its two-hundred day simple moving average is GBX 0.40. Oxford BioDynamics has a one year low of GBX 0.22 and a one year high of GBX 1.60. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80.

Wall Street Analyst Weigh In

Separately, Shore Capital reissued a “house stock” rating on shares of Oxford BioDynamics in a research note on Wednesday, October 8th.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.